IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia
Status:
Terminated
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Post-procedure myalgia (muscle ache) is a well-known and common complication of
Electro-convulsive Treatment (ECT). Myalgias are a serious concern of patients and occur in
approximately 50% of these cases. The pain is usually described as muscle soreness, similar
to that resulting from strenuous exercise. The myalgias typically begin shortly after the
procedure, lasting approximately 2-7 days in total. A recent study reported that 89% of
patients considered prevention significant and would be willing to pay a median of $33 out of
pocket to avoid this side effect. In addition to patient discomfort, myalgias can have a
further financial burden if these patients are unable to return to work or resume previous
daily activities in the days following the procedure. An agent that could treat and possibly
even prevent these myalgias has the potential to be very beneficial to these patients. IV
ibuprofen (trade name Caldolor) is a novel therapeutic modality approved by the US Food and
Drug Administration (FDA) in June 2009 for the treatment of mild to moderate pain, as an
adjunct to opioid analgesics, and for the reduction of fever.